Corcept Therapeutics Incorporated (NASDAQ:CORT) Director David L. Mahoney sold 23,006 shares of the firm’s stock in a transaction that occurred on Wednesday, July 19th. The stock was sold at an average price of $12.50, for a total transaction of $287,575.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Corcept Therapeutics Incorporated (NASDAQ CORT) traded up 0.54% during mid-day trading on Thursday, hitting $12.95. 953,569 shares of the stock traded hands. The stock’s 50 day moving average is $11.86 and its 200-day moving average is $10.06. The company has a market cap of $1.47 billion, a price-to-earnings ratio of 118.81 and a beta of 2.05. Corcept Therapeutics Incorporated has a 12 month low of $5.24 and a 12 month high of $13.25.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Monday, May 1st. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.01. The business had revenue of $27.60 million for the quarter, compared to the consensus estimate of $25.53 million. Corcept Therapeutics had a net margin of 13.51% and a return on equity of 33.97%. The business’s revenue was up 71.9% compared to the same quarter last year. On average, equities research analysts anticipate that Corcept Therapeutics Incorporated will post $0.26 EPS for the current year.

WARNING: “Corcept Therapeutics Incorporated (CORT) Director Sells $287,575.00 in Stock” was first posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/07/20/corcept-therapeutics-incorporated-cort-director-sells-287575-00-in-stock.html.

A number of research firms have weighed in on CORT. BidaskClub lowered shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, June 15th. Zacks Investment Research raised shares of Corcept Therapeutics from a “hold” rating to a “strong-buy” rating and set a $14.00 target price on the stock in a research note on Wednesday. TheStreet raised shares of Corcept Therapeutics from a “c+” rating to a “b” rating in a research note on Monday, May 22nd. Piper Jaffray Companies set a $18.00 target price on shares of Corcept Therapeutics and gave the stock a “buy” rating in a research note on Monday, May 15th. Finally, Ladenburg Thalmann Financial Services set a $20.00 target price on shares of Corcept Therapeutics and gave the stock a “buy” rating in a research note on Tuesday. One research analyst has rated the stock with a sell rating, four have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $14.20.

Institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC purchased a new position in shares of Corcept Therapeutics during the first quarter valued at about $153,000. Prudential Financial Inc. purchased a new position in shares of Corcept Therapeutics during the first quarter valued at about $198,000. Trexquant Investment LP purchased a new position in shares of Corcept Therapeutics during the first quarter valued at about $202,000. Sheets Smith Wealth Management purchased a new position in shares of Corcept Therapeutics during the second quarter valued at about $283,000. Finally, Turner Investments LLC purchased a new position in shares of Corcept Therapeutics during the first quarter valued at about $349,000. 53.52% of the stock is currently owned by institutional investors and hedge funds.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).

Insider Buying and Selling by Quarter for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Ratings for Corcept Therapeutics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.